Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DNTH - Dianthus Therapeutics Inc


IEX Last Trade
28.915
0.145   0.501%

Share volume: 158,771
Last Updated: Fri 30 Aug 2024 09:59:10 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$28.77
0.15
0.50%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
1.87%
1 Month
-0.96%
3 Months
39.28%
6 Months
19.63%
1 Year
3,649.02%
2 Year
1,605.92%
Key data
Stock price
$28.92
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.68 - $33.77
52 WEEK CHANGE
$37.74
MARKET CAP 
846.285 M
YIELD 
N/A
SHARES OUTSTANDING 
29.354 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
-5.51
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$167,166
AVERAGE 30 VOLUME 
$159,103
Company detail
CEO: Jason Gardner
Region: US
Website: https://www.magentatx.com/
Employees: 81
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.

Recent news